| answer text |
<p>NHS England and NHS Improvement are using extant systems to monitor use of the
newly rescheduled unlicensed cannabis-based products for medicinal use in England.
In England, these systems monitor the number of items dispensed and associated costs
in primary care and the volume of products used and associated cost in secondary care.
NHS England and NHS Improvement Controlled Drug Accountable Officers are also collecting
local intelligence in both the National Health Service and independent sector.</p><p>The
NHS Business Services Authority (NHSBSA) is only able to provide information on prescriptions
for cannabis-based medicines that have been prescribed and submitted to the NHS Business
Services Authority. It does not hold information on prescriptions for cannabis-based
medicines which have been issued but not fulfilled.</p><p>The following table shows
the number of items for Nabilone and Sativex (licensed cannabis-based medicines) and
unlicensed cannabis-based medicines that were prescribed on a NHS prescription, dispensed
in the community and submitted to the NHS Business Services Authority for reimbursement
between November 2018 and June 2019.</p><table><tbody><tr><td rowspan="2"><p>Month</p></td><td
colspan="2"><p>Licensed cannabis-based medicines</p></td><td rowspan="2"><p>Unlicensed
cannabis-based medicines</p></td></tr><tr><td><p>Nabilone</p></td><td><p>Sativex</p></td></tr><tr><td><p>November
2018</p></td><td><p>46</p></td><td><p>175</p></td><td><p>2</p></td></tr><tr><td><p>December
2018</p></td><td><p>49</p></td><td><p>181</p></td><td><p>1</p></td></tr><tr><td><p>January
2019</p></td><td><p>44</p></td><td><p>167</p></td><td><p>2</p></td></tr><tr><td><p>February
2019</p></td><td><p>36</p></td><td><p>159</p></td><td><p>1</p></td></tr><tr><td><p>March
2019</p></td><td><p>51</p></td><td><p>171</p></td><td><p>2</p></td></tr><tr><td><p>April
2019</p></td><td><p>49</p></td><td><p>156</p></td><td><p>2</p></td></tr><tr><td><p>May
2019</p></td><td><p>59</p></td><td><p>176</p></td><td><p>2</p></td></tr><tr><td><p>June
2019</p></td><td><p>47</p></td><td><p>187</p></td><td><p>0</p></td></tr><tr><td><p>Total</p></td><td><p>381</p></td><td><p>1,372</p></td><td><p>12</p></td></tr></tbody></table><p><strong>
</strong></p><p>In addition to the above, 185 patients have accessed Epidiolex/Epidyolex
though the manufacturer’s (GW Pharma) early access programmes ahead of a licensing
decision by the European Medicines Agency.</p>
|
|
